Topic summary

Coming back to: Telehealth prescribing models in the US

Regional › North America telehealth FDA compounding insurance

This is a generated summary. It shows the 5 most-liked posts from a topic of 31, in their original order, with the accepted answer included where one exists. It is a reading aid and it will miss nuance — the full topic is the record.

t.demirTL2 Moderator6 Jul 2026#7

e.mwangi, post #5: Prior authorisation, step therapy, and exclusion of weight-management indications from coverage are common access barriers. The denial letter tells you which barrier you are facing. Go to post

Indigenous healthcare systems: different indigenous healthcare systems have different medication access. Pathways through tribal health systems differ from mainstream healthcare.

27 likes in reply to #5 21d

e.lokkenTL2 Moderator10 Jul 2026#10

On post #6 — agreed on the reasoning, with one qualification.

Private insurance gaps: some people have private insurance but medication is not covered. Manufacturer assistance programmes are the main resource for cost reduction.

26 likes 18d

FairweatherTL2Member15 Jul 2026#16

I disagree with the reply above, and I think the disagreement is substantive rather than terminological.

The distinction being drawn does not survive when you look at the published data for this specific question. I would be glad to be shown wrong on this, because the version I am arguing against is more convenient.

30 likes 13d

a.stephanopoulosTL3Regular18 Jul 2026#20

Prior authorisation, step therapy, and exclusion of weight-management indications from coverage are common access barriers. The denial letter tells you which barrier you are facing.

22 likes 9d

k.roosTL2 Moderator22 Jul 2026#24

e.lokken, post #10: On post #6 — agreed on the reasoning, with one qualification. Private insurance gaps: some people have private insurance but medication is not covered. Manufacturer assistance programmes are the main resource for cost reduction. Go to post

Compounding pharmacies: pharmaceutical compounding of a drug not on the FDA shortage list is substantially constrained. The landscape changed when supply normalised. Current compounding availability is limited.

30 likes in reply to #10 6d

Read the full topic (31 posts)

Suggested topics

Topic	Participants	Replies	Views	Activity
About the North America category Regional › North America FDA compounding insurance Pinned Wiki US and Canadian regulation, compounding, and coverage. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is recorded with its author and a note. If the scope…	+3	7	43k	9mo
Second pass at: Coverage in the US: a map of the usual obstacles Regional › North America insurance telehealth compounding FDA On the subject in the title: Second pass at: Coverage in the US: a map of the usual obstacles Working notes rather than a conclusion. A coverage question with the paperwork detail included, since that is what…		4	62k	9mo
Canadian access and provincial variation Regional › North America compounding telehealth FDA insurance Posting this under the heading it deserves: Canadian access and provincial variation Everything below is what sits behind that. Documenting an access outcome, dated, because everything in this category…	+74	80	7.7k	18mo
State-level differences that actually matter Regional › North America compounding telehealth insurance FDA Solved On the subject in the title: State-level differences that actually matter Working notes rather than a conclusion. Documenting an access outcome, dated, because everything in this category expires. As of…	+6	10	56k	10mo
Coverage in the US: a map of the usual obstacles Regional › North America FDA insurance telehealth compounding Coverage in the US: a map of the usual obstacles — setting out what I have, and where I think it stops being reliable. A coverage question with the paperwork detail included, since that is what determines the…	+46	50	7.9k	5mo

Related topics — sharing the tags telehealth, FDA, compounding

Topic	Participants	Replies	Views	Activity
Follow-up: External review after an internal denial Access › Insurance & coverage prior authorisation formulary insurance Solved Posting this under the heading it deserves: External review after an internal denial Everything below is what sits behind that. A coverage question with the paperwork detail included, since that is what…	+6	10	12k	15h
Cost per milligram, computed honestly across formats — the long version Access › Pricing cost per milligram compounding formulary data table Cost per milligram, computed honestly across formats — the long version Writing it up because I had to work it out twice and would rather nobody else did. A coverage question with the paperwork detail…	+111	124	24k	14mo
Prescription portability between countries Access › International personal import MHRA telehealth EMA Wiki Prescription portability between countries — setting out what I have, and where I think it stops being reliable. A coverage question with the paperwork detail included, since that is what determines the…	+104	114	6.1k	3h
Manufacturer assistance programmes and their eligibility rules Access › Pricing formulary data table compounding On the subject in the title: Manufacturer assistance programmes and their eligibility rules Working notes rather than a conclusion. Documenting an access outcome, dated, because everything in this category…	+37	42	32k	11d
Personal import allowances, compared — a second dataset Access › International personal import telehealth MHRA EMA Wiki Personal import allowances, compared — a second dataset — setting out what I have, and where I think it stops being reliable. A coverage question with the paperwork detail included, since that is what…	+124	132	9.2k	2mo